Legacy Private Trust Co. Purchases 3,047 Shares of Johnson & Johnson (NYSE:JNJ)

Legacy Private Trust Co. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,173 shares of the company’s stock after acquiring an additional 3,047 shares during the period. Legacy Private Trust Co.’s holdings in Johnson & Johnson were worth $5,665,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the third quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Activest Wealth Management bought a new position in Johnson & Johnson during the third quarter worth $40,000. Finally, Morton Brown Family Wealth LLC grew its holdings in Johnson & Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock worth $41,000 after purchasing an additional 200 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ traded down $4.13 on Wednesday, hitting $142.10. The company’s stock had a trading volume of 11,025,219 shares, compared to its average volume of 7,857,323. The company’s 50 day simple moving average is $150.75 and its 200-day simple moving average is $156.23. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $141.44 and a 12 month high of $168.85. The firm has a market cap of $342.12 billion, a P/E ratio of 20.56, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.66 earnings per share. Analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Bank of America reaffirmed a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.